Journal article · 2018 · Open access

1642. Safety and Efficacy of Bacteriophage Therapy: Analysis of Clinical Case Series Data

Saima Aslam, Timothy L. Gilbey, Susan Maddocks, Sandra Morales, Susan M. Lehman, Steven D. Branston, Aleksandra Petrović Fabijan, Carrie-Lynn Langlais Furr, Francisco Rosas, Igor P. Bilinsky, Paul Grint, Robert Turner Schooley and 1 more

Open Forum Infectious Diseases, 5(suppl_1), S47 · Published 1 November 2018 · DOI 10.1093/ofid/ofy209.112

Read the free full textCite this paper

In brief

“1642. Safety and Efficacy of Bacteriophage Therapy: Analysis of Clinical Case Series Data” is a 2018 journal article by Saima Aslam and 12 co-authors, published in Open Forum Infectious Diseases. OpenAlex counts 6 citations as of 15 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Open Forum Infectious Diseases.

Citations
6
Most cited in
2019 (2)
Authors
13

Abstract

Background Bacteriophage therapy (BT) is a re-emerging strategy to treat antibiotic-resistant infections. Here, we describe our initial experience with intravenous (IV) and inhaled BT to treat life-threatening Staphylococcus aureus and Pseudomonas aeruginosa infections not responding to antibiotic therapy. Emergency Investigational New Drug application approvals (United States) or Special Access Scheme Category A notifications (Australia) and informed consent from the patients were obtained. Methods Patients were treated with AB-SA01 (3-phage product targeting S. aureus) and AB-PA01 (4-phage product targeting P. aeruginosa) produced in a Good Manufacturing Practice-certified facility. Pre- and posttreatment bacterial isolates were tested for phage susceptibility during BT. In all cases, concomitant antibiotics were continued. Safety was assessed clinically and using laboratory parameters with up to 90 days of follow-up. Samples to assess bacterial loads, bacteriophage kinetics in blood, and immune responses to phage were collected. Results As of April 2018, 8 patients were treated with BT; 5 with AB-SA01 (bacteremia, n = 4; endocarditis, n = 1) and 3 with AB-PA01 (lung infection, n = 3). Median duration of BT was 14 days and treated patients received over 90 IV doses of AB-SA01 (3 × 109 PFU/dose) and over 490 IV and nebulized doses of AB-PA01 (4 × 109 PFU/dose). BT was well tolerated, with no treatment-related adverse events. Clinical treatment success was documented in 75% of patients. Isolates collected during therapy showed ongoing susceptibility to the BT products with changes in sensitivity to the individual phage components observed in some cases. Bacteriophage kinetics revealed bloodstream clearance within a few hours after IV infusion, with an inferred initial bacteria:bacteriophage ratio of ~200 for the bacteremia patients. Conclusion BT was well tolerated as an adjunct to antibiotics, with several examples presented of microbiological eradication and improvement of objective clinical criteria. BT appears to be a safe adjunct to antibiotic therapy in life-threatening S. aureus and P. aeruginosa infections and is a promising candidate for controlled clinical trials. Disclosures S. Morales, AmpliPhi Biosciences: Employee, Salary. S. Lehman, AmpliPhi Biosciences: Employee, Salary. S. Branston, AmpliPhi Biosciences: Employee, Salary. A. Petrovic Fabijan, AmpliPhi Biosciences: Collaborator, Research support. C. L. Langlais Furr, AmpliPhi Biosciences: Employee, Salary. F. Rosas, AmpliPhi Biosciences: Employee, Salary. I. Bilinsky, AmpliPhi Biosciences: Employee and Shareholder, Salary. P. Grint, AmpliPhi Biosciences: Board Member, Employee and Shareholder, Salary. J. Iredell, AmpliPhi Biosciences: Collaborator, Research support.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Aslam, S., Gilbey, T. L., Maddocks, S., Morales, S., Lehman, S. M., Branston, S. D., Fabijan, A. P., Furr, C.-L. L., Rosas, F., Bilinsky, I. P., Grint, P., Schooley, R. T., & Iredell, J. R. (2018). 1642. Safety and Efficacy of Bacteriophage Therapy: Analysis of Clinical Case Series Data. Open Forum Infectious Diseases, 5(suppl_1), S47. https://doi.org/10.1093/ofid/ofy209.112

MLA 9

Aslam, Saima, et al. “1642. Safety and Efficacy of Bacteriophage Therapy: Analysis of Clinical Case Series Data.” Open Forum Infectious Diseases, vol. 5, no. suppl_1, 2018, p. S47. https://doi.org/10.1093/ofid/ofy209.112.

Chicago

Aslam, Saima, Timothy L. Gilbey, Susan Maddocks, Sandra Morales, Susan M. Lehman, Steven D. Branston, Aleksandra Petrović Fabijan, et al. 2018. “1642. Safety and Efficacy of Bacteriophage Therapy: Analysis of Clinical Case Series Data.” Open Forum Infectious Diseases 5 (suppl_1): S47. https://doi.org/10.1093/ofid/ofy209.112.

Harvard

Aslam, S. et al. (2018) ‘1642. Safety and Efficacy of Bacteriophage Therapy: Analysis of Clinical Case Series Data’, Open Forum Infectious Diseases, 5(suppl_1), p. S47. doi:10.1093/ofid/ofy209.112.

IEEE

S. Aslam et al., “1642. Safety and Efficacy of Bacteriophage Therapy: Analysis of Clinical Case Series Data,” Open Forum Infectious Diseases, vol. 5, no. suppl_1, p. S47, 2018, doi: 10.1093/ofid/ofy209.112.

BibTeX

@article{aslam2018safety,
  title     = {{1642. Safety and Efficacy of Bacteriophage Therapy: Analysis of Clinical Case Series Data}},
  author    = {Aslam, Saima and Gilbey, Timothy L. and Maddocks, Susan and Morales, Sandra and Lehman, Susan M. and Branston, Steven D. and Fabijan, Aleksandra Petrović and Furr, Carrie-Lynn Langlais and Rosas, Francisco and Bilinsky, Igor P. and Grint, Paul and Schooley, Robert Turner and Iredell, Jonathan R.},
  journal   = {Open Forum Infectious Diseases},
  year      = {2018},
  volume    = {5},
  number    = {suppl_1},
  pages     = {S47},
  doi       = {10.1093/ofid/ofy209.112},
  url       = {https://doi.org/10.1093/ofid/ofy209.112}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201922
202011
202211
202311
202511

Topic and keywords

Life Sciences › Immunology and Microbiology › Virology › Bacteriophages and microbial interactions

  • phage therapy
  • Staphylococcus aureus infection
  • Pseudomonas aeruginosa infection
  • bacteremia
  • endocarditis
  • antibiotic-resistant infections
  • phage susceptibility
  • adjunctive antibiotic therapy

Work with this paper

Most-cited papers in Immunology and Microbiology

All highly cited Immunology and Microbiology papers

Questions about this paper

How do I cite this paper in APA style?

Aslam, S., Gilbey, T. L., Maddocks, S., Morales, S., Lehman, S. M., Branston, S. D., Fabijan, A. P., Furr, C.-L. L., Rosas, F., Bilinsky, I. P., Grint, P., Schooley, R. T., & Iredell, J. R. (2018). 1642. Safety and Efficacy of Bacteriophage Therapy: Analysis of Clinical Case Series Data. Open Forum Infectious Diseases, 5(suppl_1), S47. https://doi.org/10.1093/ofid/ofy209.112

How many times has this paper been cited?

6 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at Open Forum Infectious Diseases.

Who wrote this paper?

Saima Aslam, Timothy L. Gilbey, Susan Maddocks, Sandra Morales, Susan M. Lehman, Steven D. Branston, Aleksandra Petrović Fabijan, Carrie-Lynn Langlais Furr, Francisco Rosas, Igor P. Bilinsky, Paul Grint, Robert Turner Schooley and 1 more.

What is the DOI of this paper?

10.1093/ofid/ofy209.112. The permanent link is https://doi.org/10.1093/ofid/ofy209.112.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.